Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults

• DOI: 10.1016/j.vaccine.2006.09.049
• Publication Date: 2006-09-30T11:24:00Z
• Authors: Dang Duc Anh; Do Gia Canh; Anna Lena Lopez; Vu Dinh Thiem; Phan Thi Long; Nguyen Hong Son; Jacqueline Deen; Lorenz von Seidlein; Rodney Carbis; Seung Hyun Han; Seong Hye Shin; Stephen Attridge; Jan Holmgren; John Clemens
• Keywords: Cholera vaccine; Cholera; Bivalent (engine); Vietnamese; ELISPOT; Regimen

Vietnam currently produces an orally administered, bivalent (O1 and O139) killed whole-cell vaccine and is the only country in the world with endemic cholera to use an oral cholera vaccine in public health practice. In order to allow international use, the vaccine had to be reformulated to meet World Health Organization (WHO) requirements. We performed a randomized, placebo controlled, safety and immunogenicity studies of this reformulated vaccine among Vietnamese adults. One hundred and forty-four subjects received the two-dose regimen and 143 had two blood samples obtained for analysis. We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic.